October 25, 2021
Concentration of Evobrutinib, a Brutons Tyrosine Kinase Inhibitor, in Cerebrospinal Fluid during Treatment of Patients with Relapsing Multiple Sclerosis in a Phase 2 Study
Background: Evobrutinib, a highly selective Brutons tyrosine kinase (BTK) inhibitor, demonstrated a low annualized relapse rate (75mg...
October 25, 2021
The Effect of Evobrutinib, a Brutons Tyrosine Kinase Inhibitor, on Blood Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis
Background: Evobrutinib is a highly selective Brutons tyrosine kinase inhibitor targeting B cells and myeloid cells. A phase 2 randomized...
Poster-Disease-modifying Therapy
October 25, 2021
Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study
Background: In a 48-week Phase II study NCT02975349, in patients with relapsing multiple sclerosis, evobrutinib was generally...
Poster-Disease-modifying Therapy
October 25, 2021
Classic-MS: Long-Term Efficacy and Real-World Treatment Patterns for Patients with Relapsing Multiple Sclerosis Who Received Cladribine Tablets in Phase III Parent Trials
Background: CLASSIC-MS (NCT03961204) explores the long-term efficacy and durability of effect of cladribine tablets (CladT; cumulative dose...
Poster-Disease-modifying Therapy
October 25, 2021
Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections and COVID-19
Background: Several integrated analyses have reported on the safety of cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years...
Poster-Disease-modifying Therapy
October 25, 2021
Click-MS: Cladribine Tablets in Patients with Relapsing Multiple Sclerosis after Suboptimal Response to Prior Injectable Disease-Modifying Therapy (Interim Analysis 1)
Background: The efficacy and safety of cladribine tablets 3.5 mg/kg (cumulative dose over 2 years) have been shown in patients with...
Poster-Disease-modifying Therapy
October 25, 2021
Evobrutinib Efficacy Is Maintained over Two Years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis
Background: Evobrutinib is a highly selective Bruton’s tyrosine kinase inhibitor with dual mode of action, targeting B cells and...